Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma research hub

NXP800 in subjects with Ovarian Cancer

This early-stage study is looking at a new medicine called NXP800 for women with certain types of ovarian, fallopian tube, or primary peritoneal cancer that hasn't responded to previous platinum-based treatment. It's the first time this drug is being given to people.